Neuren Pharmaceuticals Limited (NEU) Price & Analysis

Compare

278 Followers

NEU Stock Chart & Stats

AU$12.90

-AU$0.38(-3.05%)

At close: Jan 09 4:00 PM EST

AU$12.90

-AU$0.38(-3.05%)

Day’s Range― - ―

52-Week RangeAU$8.61 - AU$22.99

Previous CloseN/A

Volume294.48K

Average Volume (3M)305.98K

Market Cap

AU$1.61B

Enterprise ValueAU$1.61B

Total Cash (Recent Filing)AU$299.54M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)11.0

Beta2.32

Next Earnings

Feb 26, 2026

EPS Estimate

0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.12

Shares Outstanding126,639,530

10 Day Avg. Volume278,541

30 Day Avg. Volume305,983

Financial Highlights & Ratios

PEG Ratio-1.07

Price to Book (P/B)4.39

Price to Sales (P/S)7.49

P/FCF Ratio-141.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$25.61

Price Target Upside98.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free balance sheet with A$363.9m equity and A$409.7m assets materially lowers financial risk and preserves strategic optionality. This funding flexibility supports sustained R&D investment, partnering or licensing, and resilience through product commercialization cycles without reliance on external debt.

High Reported ProfitabilityVery high reported EBIT and net margins reflect a low-capex, partner/royalty-driven model that can generate outsized profitability per revenue dollar. Durable margins provide a cushion for funding pipeline programs and absorbing commercial variability, supporting long-term investment in next-generation assets.

Partner-driven, Scalable Revenue ModelA partnership/licensing model (notably with Acadia for DAYBUE) enables Neuren to scale revenue without building large commercial infrastructure. Royalties and milestone structures can produce recurring, scalable cash flows while allowing the company to concentrate resources on R&D and pipeline advancement over the medium term.

Bears Say

Earnings-to-cashflow DisconnectNegative operating and free cash flow in 2024 despite strong accounting earnings signals timing, working-capital swings or non-cash items are affecting cash conversion. Persistent disconnects reduce internal funding capacity for development and increase reliance on partner receipts or external financing for sustained operations.

Revenue Volatility And Recent DeclineSharp revenue swings—growth from very small base to A$213.2m followed by a 2024 decline—indicate earnings are sensitive to lumpy milestone/royalty timing and partner execution. This volatility complicates forecasting, planning and consistent funding of long-term R&D without contingency financing.

Concentration On Partner Commercialization & Small TeamHeavy reliance on a partner for commercialization and a tiny internal team (8 employees) limits Neuren's direct control over sales, launches and market feedback. This concentration raises execution risk, constrains agility in market expansion, and increases dependence on partner performance and contract terms.

Neuren Pharmaceuticals Limited News

Neuren Pharmaceuticals Launches On-Market Share Buy-Back

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an announcement. Neuren Pharmaceuticals Limited has announced a new on-market...

7d ago

Neuren Schedules Investor Webinar as Rare Neurology Portfolio Advances

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) just unveiled an announcement. Neuren Pharmaceuticals will host an investor webinar on...

7d ago

Neuren launches on-market buy-back as board flags undervalued shares

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has provided an update. Neuren Pharmaceuticals has launched an on-market share buy-back...

7d ago

Neuren Doses First Patient in Landmark Phase 3 Trial for Phelan-McDermid Syndrome

An update from Neuren Pharmaceuticals Limited ( ($AU:NEU) ) is now available. Neuren Pharmaceuticals has dosed the first...

12d ago

Neuren Set to Benefit as US Extends Rare Pediatric Disease Voucher Program to 2029

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) just unveiled an announcement. Neuren Pharmaceuticals has highlighted the reauthorization by the...

13d ago

Neuren Gains FDA Feedback Charting NNZ-2591 Path in HIE and Pitt Hopkins

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) just unveiled an update. Neuren reported that FDA written feedback validated its...

14d ago

Neuren Faces EU Setback as EMA Panel Issues Negative Trend Vote on Trofinetide for Rett Syndrome

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has provided an update. Neuren Pharmaceuticals disclosed that its licensee Acadia Pharmaceuticals...

15d ago

Neuren Defends Timely Disclosure of Material DAYBUE Sales Projections to ASX

Neuren Pharmaceuticals Limited ( ($AU:NEU) ) has issued an announcement. Neuren Pharmaceuticals has confirmed to the ASX that...

1M ago

Neuren’s Partner Acadia Sees DAYBUE Sales Climbing to US$700m by 2028

An update from Neuren Pharmaceuticals Limited ( ($AU:NEU) ) is now available. Neuren Pharmaceuticals reported that its partner...

1M ago

Neuren’s Phase 3 NNZ-2591 Trial Targets a High-Value Niche in Phelan-McDermid Syndrome

Neuren Pharmaceuticals Limited ($NURPF) announced an update on their ongoing clinical study. Study Overview Neuren Pharmaceuticals Limited is...

1M ago

NURPF

NEU FAQ

What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?

Neuren Pharmaceuticals Limited lowest share price was AU$8.61 and its highest was AU$22.98 in the past 12 months.

What is Neuren Pharmaceuticals Limited’s market cap?

Neuren Pharmaceuticals Limited’s market cap is AU$1.61B.

When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?

Neuren Pharmaceuticals Limited’s upcoming earnings report date is Feb 26, 2026 which is in 8 days.

How were Neuren Pharmaceuticals Limited’s earnings last quarter?

Neuren Pharmaceuticals Limited released its earnings results on Aug 26, 2025. The company reported AU$0.119 earnings per share for the quarter, beating the consensus estimate of AU$0.116 by AU$0.003.

Is Neuren Pharmaceuticals Limited overvalued?

According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Neuren Pharmaceuticals Limited pay dividends?

Neuren Pharmaceuticals Limited does not currently pay dividends.

What is Neuren Pharmaceuticals Limited’s EPS estimate?

Neuren Pharmaceuticals Limited’s EPS estimate is 0.01.

How many shares outstanding does Neuren Pharmaceuticals Limited have?

Neuren Pharmaceuticals Limited has 126,639,530 shares outstanding.

What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?

Neuren Pharmaceuticals Limited reported an EPS of AU$0.119 in its last earnings report, beating expectations of AU$0.116. Following the earnings report the stock price went up 6.742%.

Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in AU:NEU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neuren Pharmaceuticals Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

54.79%

Trailing 12-Months

Asset Growth

42.47%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Neuren Pharmaceuticals Limited (NEU) Earnings & Revenues

Historic Earnings Reports

NEU Stock 12 Month Forecast

Average Price Target

AU$25.61

▲(98.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"AU$10","31":"AU$31","15.25":"AU$15.25","20.5":"AU$20.5","25.75":"AU$25.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.500000053974325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$30.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.6124958817,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$25.61</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.20000003751658,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$21.20</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,15.25,20.5,25.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.25,17.34615385030572,18.442307700611433,19.53846155091715,20.63461540122287,21.730769251528585,22.826923101834304,23.923076952140022,25.01923080244574,26.115384652751455,27.211538503057174,28.30769235336289,29.403846203668607,{"y":30.500000053974325,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.25,16.9701919909,17.6903839818,18.4105759727,19.1307679636,19.8509599545,20.5711519454,21.2913439363,22.0115359272,22.7317279181,23.451919909,24.1721118999,24.8923038908,{"y":25.6124958817,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.25,16.630769233655123,17.011538467310242,17.392307700965365,17.773076934620487,18.153846168275606,18.53461540193073,18.915384635585852,19.296153869240975,19.676923102896094,20.057692336551217,20.438461570206336,20.81923080386146,{"y":21.20000003751658,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.49,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.76,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.61,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.25,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >